Publications & Presentations

Presentation

Phase 1, Randomized, Placebo-Controlled Single-Ascending Dose Trial of GFB-024, a once-monthly CB1 inverse agonist, in Healthy Overweight and Obese Participants

Edwin Tucker, Gregory Gaich, Sanela Bilic, John Lawler, Yossi Dagon, Thomas A. Gustafson, Leslie Johnson, Lori Rudolph-Owen

  • ENDO 2022
  • June 11-14, 2022
  • Atlanta, Georgia
Poster

Phase 1, Randomized, Controlled Trial of GFB-024, a Once-Monthly CB1 Inverse Agonist, in Healthy Overweight and Obese Participants and in Participants with Type 2 Diabetes Mellitus

Edwin Tucker, Gregory Gaich, Sanela Bilic, John Lawler, Yossi Dagon, Thomas A. Gustafson, Leslie Johnson, Lori Rudolph-Owen

  • American Diabetes Association 2022 Annual Meeting
  • June 3-7, 2022
  • New Orleans, LA / Hybrid
Poster

Subset analysis of The HALO Survey evaluating the impact of side effects of medications in patients with glomerular disease

Amanda Grandinetti, Kirk Campbell, Agnes Costello, Kent Bressler, Jill Hammonds, Kristen Hood, Joseph Kennedy, Liz Melone, Shannon Mulroy, Dine Watson, Eric Duhaime

  • NKF Spring Clinical Meeting
  • April 6-10, 2022
  • Boston, MA
Publication

Discovery and Optimization of Highly Selective Inhibitors of CDK5

Matthew H. Daniels, Goran Malojcic, Susan L. Clugston, Brett Williams, Marie Coeffet-Le Gal, Xin-Ru Pan-Zhou, Srinivasan Venkatachalan, Jean-Christophe Harmange, Mark Ledeboer

Poster

Identification of kidney disease diagnoses in patients with diabetes by biopsies and electronic health records

Eva Fast, Cami R. Jones, Kenn B. Daratha, Susanne B. Nicholas, Radica Z. Alicic, Cynthia C. Nast, Jonathan E. Zuckerman, Sarthak Patel, Ken Allison, Adam Tebbe, Michelle Penny, Keith C. Norris, Katherine R. Tuttle.

  • 2021 American Society of Nephrology Kidney Week
  • November 4-8, 2021
  • Virtual